



NCTN Sarcoma Trials Portfolio (Open as of 10/15/2024)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Sarcoma Trials (Open as of 10/15/2024)

Protocol Number	Phase	Protocol Title
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AOST2032	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
ARST2031	III	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
EA7211	III	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
EA7222	III	A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	II	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
EAY191-E4	II	Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
EAY191-N5	II	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EAY191-S3	II	Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial